The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia

American Journal of Medicine

Volumn 102, Issue 4, 1997, Pages 387-391

  Fong, Ronald L ^a   Ward, Harry J ^a  

^a KING DREW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LOW FAT DIET; MALE; NEGRO; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED;

EID: 0030914522     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00091-0     Document Type: Article

References (32)

1. Levine GL, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. NEJM. 332:1995;512-521.
2. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different countries. Twenty-five year follow-up of the Seven Countries Study. JAMA. 274:1995;131-136.
3. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. NEJM. 325:1991;373-381.
4. Maher VM, Thompson GR. HMG-CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin. Q J Med. 274:1990;165-175.
5. Malini PL, Ambrosioni E, De Divitiis O, et al. Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia. Clin Ther. 13:1991;500-510.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 333:1995;1301-1307.
7. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
8. Jacobson TA, Chin MM, Curry CL, et al. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch Intern Med. 1995:1900-1906.
9. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol. 66:1990;44B-55B.
10. Prisant LM, Downton M, Watkins LO, et al. Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Am J Cardiol. 78:1996;420-424.
11. Naumburg EH, Franks P, Bell B, et al. Racial differentials in the identification of hypercholesterolemia. J Fam Prac. 36:1993;425-430.
12. Rehak NN, Elin RJ, Chesler R, Johnson E. Comparison of the Du Pont aca and Dow methods for determination of high-density lipoprotein cholesterol. Clin Chem. 30:1984;127-129.
13. Lolekha PH, Nitipaichit P. User-defined serum aspartate and alanine aminotransferase, cholesterol, triglycerides, urea, and uric acid for the Beckman syncrom CS 4.5 using Ames Sera-Pak reagents. J Clin Lab Anal. 6:1993;245-256.
14. Friedwald WT, Levy RI, Frederickson PS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
15. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
16. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 36:1982;936-942.
17. Stalenhoef AF, Lansberg PJ, Kroon AA, et al. Treatment of primary hypercholesterolemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study. J Intern Med. 234:1993;77-82.
18. Chisholm A, Mann J, Sutherlands W, et al. Dietary management of patients with familial hypercholesterolemia treated with simvastatin. Q J Med. 307-308:1992;825-831.
19. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (Multicountry comparative study). Am J Cardiol. 70:1992;1281-1286.
20. The Simvastatin Pravastatin Study Group. Am J Cardiol. 171:1993;408-414.
21. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertri-glyceridemia. JAMA. 275:1996;128-133.
22. Hunninghake DB, Stein EA, Dujovne CA, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. NEJM. 328:1993;1213-1219.
23. Bradford RH, Shear CL, Cremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 151:1991;43-49.
24. Treasure CB, Klein L, Weintraub WS. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. NEJM. 332:1995;481-487.
25. Kannel WB, D'Agostino RB, Stepanians M, D'Agostino LC. Efficacy and tolerability of lovastatin in a six-month study: analysis by gender, age and hypertensive status. Am J Cardiol. 66:1990;1B-10B.
26. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 89:1994;959-968.
27. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 121:1994;641-647.
28. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work. JAMA. 274:1995;801-806.
29. Cholesterol screening and awareness-behavior risk factor surveillance system, 1990. MMWR. 41:1992;669-678.
30. Giles GH, Anda RF, Jones DH, et al. Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities. JAMA. 269:1993;1133-1138.
31. Sempos CT, Cleman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults. An update based on the guidelines from the Second Report of the National Cholesterol Education Program Adults Treatment Panel. JAMA. 269:1993;3009-3014.
32. Foster P, Jackson M. Distribution of lipoprotein phenotypes, cholesterol, and lipids in inner-city blacks. J Natl Med Assoc. 85:1993;211-215.